Hi hargo, thank you for the clarification regarding the cost savings over 3 years. I should have looked back at the original announcement. Why announce the cost savings over 3 years? Does that mean that Imugene would have incurred T cell manufacturing costs of $A49 million over next 3 years without generating any sales income over the same period! Maybe the "up to $6M USD in upfront and milestone-driven payments over three years" is the only revenue gain to Imugene. Maybe "the strategic manufacturing and process development partnership will support Imugene’s Azer-cel clinical study supply" is a guarantee of supply to Imugene at an agreed cost price.
hargo, I was aware of the Azer-cel 1 year payment in August.
Imugene acquired Azer-cel, so CHEAP in a roundabout way.
Regards.
IMU Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)